BeiGene
NASDAQ:BGNEBiotechBeijing, China, China · Est. 2010 · 7,000 employees
BeiGene is a Chinese biotechnology company developing innovative oncology and hematology treatments for both Western and Chinese markets.
10
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
12
Indications↗
Distinct diseases across all programs
158
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
10 drugs in development
Phase 32
Phase 24
Phase 13
Preclinical3
By Therapeutic Area
top 2
Oncology
982%
Immunology
19%
R&D Momentum
58/100
Pipeline Velocity
0/100
Trial Completion Rate
86/100
Pipeline Concentration
69/100
Pipeline Freshness
58/100
Strategic Signals
- ↗Active in Immunology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Oct 31, 2026
Completed
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer
Oct 27, 2026
Recruiting
A Phase 1/2 Open-label Study to Investigate the Safety of Sonrotoclax Ramp-up Schedule(s) in Adult Patients With Hematological Malignancies.
Oct 27, 2026
Recruiting
A Single-Arm, Multi-Center, Open-Label, Phase 2 Study to Evaluate Efficacy and Safety of Tislelizumab (BGB-A317), an Anti-PD-1 Monoclonal Antibody, as Monotherapy in Patients With Previously-Treated Locally Advanced Unresectable or Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors
Earlier
Oct 22, 2026TrialA Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Chinese Patients With B-Cell Malignancies
Oct 21, 2026TrialA Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors
Oct 16, 2026TrialA Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Oct 16, 2026TrialA Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Oct 1, 2026TrialA Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
4 more events
Sep 29, 2026TrialA Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor BGB-11417 in Adult Patients With Mature B-cell Malignancies
Sep 23, 2026TrialA Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BCL2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Sep 15, 2026TrialA Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies
Sep 12, 2026TrialA Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-T187, an EGFR×MET Trispecific Antibody, Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
Details
Company Info
Company Overview
$18.0B
Mkt Cap
$1.5B
Revenue
—
Cash
CEOJohn V. Oyler
Founded2010
Employees7,000
HQBeijing, China, China
ExchangeNASDAQ:BGNE
Websitebeigene.com
LinkedInCompany Page
Therapeutic Focus
OncologyOtherNephrologyRespiratoryImmunology
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Immunology
Oncology
Immunology
Oncology
Acute Myeloid Leukemia
BGB-11417Preclinical
Advanced Malignancies
BGB-A445Phase 3
OciperlimabPhase 3
Lung Cancer
OciperlimabPhase 3
Solid Tumor
BGB-B455Phase 1
Regulatory
Regulatory Timeline
20231 event
FDAJul 17
Beyfortus — BEYFORTUS
Application BLA761328
20242 events
FDAAug 22
Beyfortus — BEYFORTUS
Application BLA761328
FDAFeb 23
Beyfortus — BEYFORTUS
Application BLA761328
20251 event
FDAOct 20
Beyfortus — BEYFORTUS
Application BLA761328
20261 event
FDAApr 7
Beyfortus — BEYFORTUS
Application BLA761328
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)